← All Replimune Group, INC filings

Replimune Group, INC 8-K filings

NASDAQ
REPL
Replimune Group, INC
8-K: Replimune Announces CEO Transition and Executive Leadership Changes
Replimune Group, Inc. has announced a transition in executive leadership, with Sushil Patel appointed as CEO effective April 1, 2024, and other key changes to support the company's commercialization efforts.
NASDAQ
REPL
Replimune Group, INC
8-K: Replimune Announces Positive Clinical Trial Data and Extends Cash Runway into 2026
Replimune reported positive data from its IGNYTE trial for RP1 in melanoma, plans a BLA submission in 2H 2024, and extended its cash runway into 2H 2026.